Royalty Report: Drugs, Antibiotic, Therapeutic – Collection: 305616

$150.00

Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 8

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 8

Primary Industries

  • Drugs
  • Antibiotic
  • Therapeutic
  • Drug Discovery
  • Diagnostic
  • Disease
  • Bacterial Infection

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 305616

License Grant
Licensor grants to Licensee the exclusive, worldwide license or sublicense, as the case may be, including the right to grant sublicenses, to manufacture, use and sell Licensed Products in the Area under all Licensor right, title and interest in the Patent Rights (the License).
License Property
Licensed Product means any Product, the manufacture, use or sale of which would infringe the Patent Rights in the absence of a license or sublicense or which, if such Patent Rights are comprised of patent applications alone, the manufacture, use or sale of such Product would infringe a claim included in such applications as if such claim were issued in a patent.

Class means antibacterial agents having the same mechanism of action or pharmacophores acting on a given target.

Licensor is a biopharmaceutical company founded to discover, develop and commercialize novel antibiotics for the treatment of serious bacterial infections. The Companys discovery and development programs address the growing problem of bacterial drug resistance through two principal themes (i) Targeted Antibiotics, which focuses on developing novel antibiotics and antibiotic potentiators, and (ii) Targeted Genomics, which utilizes bacterial genetics to discover new classes of antibiotics and other novel treatments for bacterial disease.

Field of Use
The field of use is for the genetics-based screening technology to identify and subsequently develop antibacterial products.

IPSCIO Record ID: 305615

License Grant
Licensor hereby agrees to conduct the research program in consultation with Licensee with a goal of discovering, identifying and synthesizing collaboration compounds for development by Licensee into one or more licensed products for commercialization by Licensee. The research program shall be conducted in accordance with the overall research plan.
License Property
Licensed Product shall mean any collaboration compound selected for development and marketing by Licensee.

Collaboration Compound shall mean any composition of matter in the field (or in the case of pro-drugs, an active metabolite of which), other than a natural product or synthetic or semi-synthetic derivative thereof, that (i) was discovered, identified, synthesized or acquired by or on behalf of Licensor as of the effective date, (ii) is discovered, identified, synthesized or acquired by or on behalf of Licensor during the research term and for six (6) months thereafter, or (iii) is contained within a chemical genus as defined in any issued claim of any unexpired patent in the patent rights, or in a claim of a pending application for such a patent which is being prosecuted in good faith, and as to which one member of such chemical genus is defined in (i) or (ii) above. For purposes of determining whether a given composition is a collaboration compound, it is understood that a composition which is discovered, identified, synthesized or acquired during the research term or within six (6) months thereafter (the Applicable Date) shall be included as a collaboration compound notwithstanding whether the composition was identified as being active in the field after the Applicable Date.

Development shall mean all work involved in Phases O, I, II, and III for a Licensed product in any country or territory.

U.S. Serial No. 08/377,583 – Screening Procedure for Penicillin-binding protein inhibitors.

Research Program shall mean all research and development performed, directed or acquired by Licensor in the course of performing the research plan during the research term.

Licensor is a biopharmaceutical company founded to discover, develop and commercialize novel antibiotics for the treatment of serious bacterial infections. The Companys discovery and development programs address the growing problem of bacterial drug resistance through two principal themes (i) Targeted Antibiotics, which focuses on developing novel antibiotics and antibiotic potentiators, and (ii) Targeted Genomics, which utilizes bacterial genetics to discover new classes of antibiotics and other novel treatments for bacterial disease.

Field of Use
The collaboration agreement is to discover and develop novel beta-lactam antibiotics, antibiotic potentiators and inhibitors of bacterial signal transduction targeted at problematic Gram-positive bacteria, including staphylococci and enterococci.

The targeted Antibiotics programs seek to rapidly develop clinically useful antibiotics tailored to treat specific bacterial infections, as well as antibiotic potentiators, which will overcome resistance pathways and restore usefulness to existing antibiotics that have been rendered ineffective. The specific problematic bacteria being addressed (staphylococci, enterococci, Pseudomonas aeruginosa and Streptococcus pneumoniae) are responsible for 44% of the approximately two million hospital-acquired infections occurring annually in the United States.

Field shall mean the field of
(i) cephalosporin antibiotics active against Gram-positive bacteria with MICs (minimum inhibitory concentrations) of ~ 32,/g/ml against staphylococci, enterococci and pneumococci, as determined by NCCLS recommended methods;
(ii) novel compounds and compositions which react with penicillin binding protein, including but not limited to PBP2a, with an ICso ! 50,/g/ml in a standard penicillin binding protein assay, provided that research activities are initiated in this ponion of the field prior to start of the nineteenth (19th) month of the research term;
(iii) non-antibacterial beta-lactam or glycopeptide antibiotic potentiators, including specifically, but not limited to, compounds that exen their e~ect primarily by inhibition of methicillin and vancomycin resistance mechanisms, and potentiators that exen their effect primarily by inhibition of histidyl-aspartyl two component switch regulatory system in bacteria, which non-antibacterial beta-lactam or glycopeptide antibiotic potentialOr exhibits MICs (minimum inhibitory concentrations) alone, against staphylococci, enterococci and pneumococci of ~32ys/ml. as determined by NCCLS recommended methods, but not including (a) quinolone potentiators or (b) potentiators or antibacterials which work primarily by inhibition of bacterial efflux pumps, or (c) beta-lactamase inhibitors ;
(iv) compounds or compositions discovered through the use of genes, gene products and Licensor screens in the Agr (accessory gene regulator) pathway of Staphylococcus aureus, or functionally homologous genes in other Gram-positive organisms, in either instance including histidyl-aspartyl two component switch regulatory systems in the Agr pathway;
(v) antibiotics which act through the histidyl-aspartyl two component switch regulatory system discovered using Licensor know-how developed in performance of the research program during the research term, or within six (6) months thereafter (i.e., new hits and leads and new discovery screens for histidine protein kinase inhibitors developed during the course of the research program), with MICs (minimum inhibitory concentrations) of~16/lg/ml against Gram-positive and/or Gram-negative organisms, as determined by NCCLS recommended methods, all for use in treating bacterial infections for all human and animal pharmaceutical applications.

Licensee has been engaged in research efforts focused on the development of new antibacterials and has certain research, development and commercialization capabilities in the field.

IPSCIO Record ID: 148591

License Grant
Licensor grants the exclusive, worldwide license or sublicense, as the case may be, including the right to grant sublicenses, to manufacture, use, offer for sale, sell or import Licensed Products.
License Property
The Licensed Product means any Product, the manufacture, use, offer for sale, sale or import of which would infringe the Patent Rights in the absence of a license or sublicense for antibacterial agents having the same mechanism of action or pharmacophores acting on a given target.

Party established a collaboration to utilize bacterial genetic approaches with in vitro essential genes to discover products for the treatment of bacterial infections in animals.

Field of Use
The products are for Dogs, Cats, Horses and Livestock.

IPSCIO Record ID: 268565

License Grant
The joint effort will use the Parties technologies for the high-throughput characterization of novel
antiinfective drug targets and rational drug design.

Licensor grants
—  a worldwide, non-exclusive license, with the right to sublicense, under the Licensor Technology solely to perform Research in the Field with respect to Proposed Targets, Medicinal Chemistry Programs, Shared Programs and Licensee Programs during the Research Term;
—  a worldwide, exclusive license, with the right to sublicense, under the Licensor Technology to develop, make, have made, use, sell, have sold, offer for sale and import Licensee Products in the Field; and
—  a worldwide, non-exclusive license, with the right to sublicense, under the Licensor Technology to develop, make, have made, use, sell, have sold, offer for sale and import Independent Products in the Field.

License Property
Licensor is engaged in the research, development and commercialization of novel antimicrobial drugs to combat serious and life-threatening bacterial and fungal infections.

Product shall mean a Shared Product, Licensee Product, Licensor Product or Independent Product.

Pharmacophore shall mean the minimum chemical structure that provides the basis for activity of a compound against a Gene Target.

Field of Use
Field shall mean the treatment, prevention or diagnosis of bacterial or fungal infections.   As a result of the collaboration, the companies expect to accelerate the discovery of novel classes of antibiotics to treat infectious diseases, including those resistant to current therapies.

IPSCIO Record ID: 182663

License Grant
Licensor grants a global, exclusive patent and technology license for the development, manufacturing and marketing of omadacycline.  Pursuant to the Letter agreement, Licensor was granted a right of first negotiation with respect to commercialization rights of omadacycline following approval of omadacycline from the FDA, European Medicines Agency, or EMA, or any regulatory agency.
License Property
Omadacycline is the first in a new class of aminomethylcycline antibiotics.  It is an empiric monotherapy.  Empiric monotherapy refers to the use of a single, antibacterial agent to begin treatment of an infection before the specific pathogen causing the infection has been identified.
Field of Use
Licensee is a clinical stage biopharmaceutical company.  Omadacycline will be used in the emergency room, hospital and community care settings.

IPSCIO Record ID: 352727

License Grant
Licensor of Korea grants a sole and exclusive license under the Licensor Patents, Licensor Know-How, Licensor Licensed Patents and Know-how to use, import, package, sell and offer for sale Products within the Field in the Territory, as well as the exclusive right to use the Trademarks in the Territory in conjunction with the use or sale of Products.

This agreement includes a non-exclusive grant back from Licensee to Licensor.

License Property
Licensor is the owner of all right, title and interest in certain patents and know-how relating to Gemifloxacin, an antibiotic.

Active Pharmaceutical Ingredient or API means Gemifloxacin in active bulk.

Licensor Licensed Patents include but is not limited to
– Dimethane-sulfonate salt of certain pyrrolidinium compounds and the process for the
prearation thereof and the process for the preparation of gemifloxacin free base or salts using AM 19.
– The process for direct salt  and hydrate formation of gemifloxacin mesylate sesquihydrate using a water-miscible cosolvent and water.
– The process for gemifloxacin free base or salts using an agueous solvent.
– Combination Therapy (gemifloxacin and B-lactam).
– Combination Therapy (gemifloxacin and carbapenem).

The trademarks are FACTIVE, FACTIVE DEV, FACPAC3DAY, FACPAC7 and dev., and FAST. ACTIVE. FACTIVE.

DNA nanobinder compounds are compounds that exhibit significant antibacterial activity, have at least one heteroaromatic carboxamide unit, are first synthesized in an internal GS research program (including research programs funded by the United States government but excluding collaborative research programs with a non-governmental third party) and typically but not necessarily bind to the minor groove of double-stranded DNA with an affinity in the nanomolar range.

Field of Use
FACTIVE (gemifloxacin mesylate) is used to treat a variety of bacterial infections. This medication belongs to a class of drugs known as quinolone antibiotics. It works by stopping the growth of bacteria. This antibiotic treats only bacterial infections.

IPSCIO Record ID: 266779

License Grant
The joint effort will use the Parties technologies for the high-throughput characterization of novel
antiinfective drug targets and rational drug design.

Licensor grants
—  a worldwide, non-exclusive license, with the right to sublicense, under the Licensor Technology solely to perform Research in the Field with respect to Proposed Targets, Medicinal Chemistry Programs, Shared Programs and Cubist Programs during the Research Term;
—  a worldwide, exclusive license, with the right to sublicense, under the Licensor Technology to perform development activities for Shared Programs after designation of IND Candidates for such Shared Programs, to develop Licensee Products, and to make, have made, use, sell, have sold, offer for sale and import Shared Products and Licensee Products in the Field; and
—  a worldwide, non-exclusive license, with the right to sublicense, under the Licensor Technology to develop, make, have made, use, sell, have sold, offer for sale and import Independent Products in the Field.

License Property
Licensor has developed expertise and proprietary technology in the areas of structural proteomics and high-throughput rational drug design.

Product shall mean a Shared Product, Licensee Product, Licensor Product or Independent Product.

Pharmacophore shall mean the minimum chemical structure that provides the basis for activity of a compound against a Gene Target.

Field of Use
Field shall mean the treatment, prevention or diagnosis of bacterial or fungal infections.   As a result of the collaboration, the companies expect to accelerate the discovery of novel classes of antibiotics to treat infectious diseases, including those resistant to current therapies.

IPSCIO Record ID: 203561

License Grant
Licensor shall assign to Licensee Licensors entire right, title and interest in and to the Compound Patents pursuant to a patent assignment agreement executed on the same date as this Agreement and any Oxazolidinone Compound synthesized, discovered and/or developed by Licensor prior to the Effective Date.

For the research licenses, Licensor grants during the Research Term a worldwide, exclusive, with reserved rights to Licensor, a license, under the Licensor Know-how and Patents as necessary for Licensee to conduct its obligations and tasks under the Research Plan.

For the commercialization license, Licensor grants during the Term of this Agreement a worldwide, exclusive license under the Licensors Know-how and Patents to use, make, have made, market, distribute, promote, offer for sale, sell, export and import Product, including the right to grant sublicenses to Affiliates and Sublicensees.

License Property
The Compound means any composition of matter,  excluding any Oxazolidinone Compound, whether patented or not, that Licensee synthesized prior to the Effective Date, but excluding any Included Licensee Compound, or any ester, salt, hydrate, solvate or prodrug of the foregoing Compounds.

The oxazolidinone class of antibiotics is a relatively recent addition to the antimicrobial world and have been found to be especially useful in treating infections caused by Gram-positive bacteria.

The patents are for Method For Solid Phase Synthesis of Alcohol Derivatives and Resulting Compositions;  and Oxazolidinone Combinatorial Libraries, Compositions and Methods of Preparation.
This application discloses methods for the solid phase synthesis of oxazolidinones; oxazolidinone combinatorial libraries and methods for their synthesis; pharmaceutical compositions comprising bioactive oxazolidinone compounds, including those adapted for oral, topical or parenteral use for the treatment of bacterial infections; and methods of screening combinatorial libraries to detect compounds with activity for treatment of disease states such as inflammation, infection, hypertension, CNS disorders and cardiovascular disorders.

TITLE OXAZOLIDINONE COMBINATORIAL LIBRARIES, COMPOSITIONS AND METHODS OF PREPARATION
This application discloses combinatorial libraries comprising oxazolidinones; methods of preparation of the libraries; biologically active oxazolidinone compositions including compositions for use for the treatment of bacterial infections; and methods of screening combinatorial libraries to detect bioactive compounds useful for treatment of disease states such as inflammation, infection, hypertension, central nervous system disorders and cardiovascular disorders.

TITLE OXAZOLIDINONE COMBINATORIAL LIBRARIES, COMPOSITIONS AND METHODS OF PREPARATION
Biologically active oxazolidinones, libraries and pharmaceutical compositions, and methods of preparation are disclosed, wherein the biologically active oxazolidinones may be used in pharmaceutical applications including use as sedatives, anticonvulsants, muscle relaxants, anti-Parkinson agents, analgesics, antiinflammatories, local anesthetics, muscle contractants, antibiotic, antiviral, antiretroviral, antimalarials, diuretics, lipid regulating agents, antiandrogenic agents, antiparasitics, neoplastics, antineoplastics and chemotherapy agents, as well as for treatment of cardiovascular diseases, central nervous system diseases, cancer, metabolic disorders, infections and dermatological diseases as well as other biological disorders and infections.

Field of Use
The field means antibacterial use in humans.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.